GlassScriptPhysician profile
Kelley A Rone
NPI 1316352339
$28,997.67
in general payments reported to CMS, 2019-2025
9 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,624 · 2022: $220 · 2023: $3,061 · 2024: $474 · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $5,241 · Consulting Fee: $2,685 · Food and Beverage: $1,523 · Honoraria: $1,015 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,582.00 |
| Travel and Lodging | $5,240.61 |
| Consulting Fee | $2,685.00 |
| Food and Beverage | $1,522.93 |
| Honoraria | $1,015.00 |
| Education | $108.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18,077.14 | 2024-2025 | |
| Pfizer INC. | $4,323.62 | 2022-2025 | |
| Exelixis INC. | $2,952.59 | 2023 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $1,514.94 | 2021-2022 | |
| Array Biopharma INC | $720.00 | 2021 | |
| Daiichi Sankyo INC. | $483.75 | 2021 | |
| Abbvie INC. | $463.89 | 2022-2025 | |
| Incyte Corporation | $296.68 | 2023-2025 | Zynyz, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $165.06 | 2024-2025 | Lynparza, Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Rone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.